Skip to main content
. 2019 Jan 18;116(6):2226–2231. doi: 10.1073/pnas.1818865116

Fig. 5.

Fig. 5.

Inhibitory effects of GHRH antagonists on the growth of MPM in vivo. (A) Representative MSTO-211H tumors, excised at the end of the experiments, from mice s.c. injected for 4 wk with either vehicle, MIA-602, or MIA-690 (5 μg/d) (Upper). The graph shows the tumor growth curves. Results are mean ± SEM. ***P < 0.001 vs. vehicle; n = 15 in each group. (B) Tumor weight in mice treated with either vehicle or GHRH antagonists. Results are mean ± SEM. ***P < 0.001 vs. vehicle; n = 15. (C) IGF-I levels measured in tumors by ELISA. Results are mean ± SEM. *P < 0.05 vs. vehicle; n = 6. (D) VEGF mRNA assessed by real-time PCR and normalized to 18S rRNA. Results, expressed as fold change of vehicle, are mean ± SEM. **P < 0.01 and ***P < 0.001 vs. vehicle; n = 10.